Document is current
Any future updates will be listed below
-
Authors
Devaux, Yvan https://orcid.org/0000-0002-5321-8543
Zhang, Lu
Lumley, Andrew I. https://orcid.org/0000-0001-5935-3327
Karaduzovic-Hadziabdic, Kanita
Mooser, Vincent https://orcid.org/0000-0002-8632-0448
Rousseau, Simon https://orcid.org/0000-0002-8773-575X
Shoaib, Muhammad https://orcid.org/0000-0002-4854-4635
Satagopam, Venkata https://orcid.org/0000-0002-6532-5880
Adilovic, Muhamed https://orcid.org/0000-0002-5326-0944
Srivastava, Prashant Kumar
Emanueli, Costanza https://orcid.org/0000-0002-2392-0702
Martelli, Fabio https://orcid.org/0000-0002-8624-7738
Greco, Simona
Badimon, Lina https://orcid.org/0000-0002-9162-2459
Padro, Teresa https://orcid.org/0000-0003-1921-954X
Lustrek, Mitja https://orcid.org/0000-0003-3219-2935
Scholz, Markus https://orcid.org/0000-0002-4059-1779
Rosolowski, Maciej
Jordan, Marko
Brandenburger, Timo
Benczik, Bettina https://orcid.org/0000-0003-0379-2181
Agg, Bence https://orcid.org/0000-0002-6492-0426
Ferdinandy, Peter
Vehreschild, Jörg Janne https://orcid.org/0000-0002-5446-7170
Lorenz-Depiereux, Bettina
Dörr, Marcus
Witzke, Oliver
Sanchez, Gabriel
Kul, Seval
Baker, Andy H. https://orcid.org/0000-0003-1441-5576
Fagherazzi, Guy
Ollert, Markus https://orcid.org/0000-0002-8055-0103
Wereski, Ryan
Mills, Nicholas L. https://orcid.org/0000-0003-0533-7991
Firat, Hüseyin
-
Funding
Funding for this research was provided by:
European Commission (101016072)
Fonds National de la Recherche Luxembourg (C17/BM/11613033, C14/BM/8225223, COVID-19/2020-1/14719577/miRCOVID)
Italian Ministry of Health Projects
- License Information
-
More Information
Article History
Received: 11 December 2023
Accepted: 3 April 2024
First Online: 20 May 2024
Competing interests
: Y.D. holds patents and licensing agreements related to the use of RNAs for diagnostic and therapeutic purposes, and is SAB member of Firalis SA. P.F. is the founder and CEO of Pharmahungary Group, a group of R&D companies. J.J.V. has personal fees from Merck / MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Center for Infection Research (DZIF), University Hospital Freiburg/ Congress and Communication, Academy for Infectious Medicine, University Manchester, German Society for Infectious Diseases (DGI), Ärztekammer Nordrhein, University Hospital Aachen, Back Bay Strategies, German Society for Internal Medicine (DGIM), Shionogi, Molecular Health, Netzwerk Universitätsmedizin, Janssen, NordForsk, Biontech, APOGEPHA. J.J.V. has grants from Merck / MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Center for Infection Research (DZIF), German Federal Ministry of Education and Research (BMBF), Deutsches Zetrum für Luft- und Raumfahrt (DLR), University of Bristol, Rigshospitalet Copenhagen, Network University Medicine. L.B. declares to have acted as a SAB member of Sanofi, Ionnis, MSD and NovoNordisk; to have received speaker fees from Sanofi, Bayer and AB-Biotics SA and to have founded the spin-off Ivastatin Therapeutics S.L. (all unrelated to this work). T.P. declares to have received speaker fees from AB-Biotics SA, and to be a co-founder of the Spin-off Ivastatin Therapeutics S.L. (all unrelated to this work). M.S. received funding from Pfizer Inc. and from Owkin for projects not related to this research. N.L.M. has received honoraria from Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics and LumiraDx. The University of Edinburgh has received research grants from Abbott Diagnostics, Novo Nordisk, and Siemens Healthineers. H.F. is the founder and owner of Firalis SA, a company commercializing the FIMICS panel. He holds patents and licenses for the use of RNAs as biomarkers and therapeutic targets. The remaining authors declare no competing interests
